Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 3, 2001, Pages

  Doern, G V ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFDINIR; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATION; CHILD; CLONAL ANERGY; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZITHROMYCIN; BETA-LACTAM RESISTANCE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0035884888     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321847     Document Type: Conference Paper

References (65)

1. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987
2. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States
3. Increasing penicillin resistance in Streptococcus pneumoniae in the US: Effect on susceptibility to oral cephalosporins
4. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993
5. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
6. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective US study
7. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
8. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program
9. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-8
10. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
11. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics
12. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae
13. Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci
14. Alterations in PBP 1A essential for high-level penicillin resistance in Streptococcus pneumoniae
15. Alterations in penicillin-binding protein 2B from penicillin-resistant wild-type strains of Streptococcus pneumoniae
16. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States
17. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbpla-pbp2b-pbp2x-dhf restriction profiles
18. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States
19. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: Characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis
20. Penicillin-binding protein families: Evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci
21. Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center
22. Clonal and temporal patterns of nasopharyngeal penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae strains in children attending a day care center
23. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio
24. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: Evidence suggesting capsular transformation of the resistant strain in vivo
25. Pneumococcal resistance to antibiotics
26. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: A population-based study
27. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci
28. The prevalence of drug-resistant Streptococcus pneurnoniae in Atlanta
29. The continued emergence of drug-resistant pneumococcal infections in the United States
30. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study
31. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: Findings of a French survey
32. Infections caused by erythromycin resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study
33. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
34. Risk factors for the carriage of drug-resistant Streptococcus pneumoniae among Memphis, Tennessee children
35. Carriage of penicillin-resistant pneumococci in a military population in Washington, DC: Risk factors and correlation with clinical isolates
36. Antimicrobial resistance in Streptococcus pneumoniae: A South African perspective
37. Antimicrobial susceptibility of nasopharyngeal isolates of potential pathogens recovered from infants before antibiotic therapy: Implications for the management of otitis media
38. Appearance of resistance to β-lactam antibiotics during therapy for Streptococcus pneumoniae meningitis
39. Pneumococcal bacteremia during oral treatment with cefixime for otitis media
40. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcuspneumoniae and Haemophilus influenzae in children with acute otitis media
41. Otitis media: Back to basics
42. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe
43. Antimicrobial-drug use and changes in resistance in Streptococcus pneumoniae
44. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
45. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin
46. Comparison of bronchopulmonary pharmacokinetics of darithromycin and azithromycin
47. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in health adult volunteers
48. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects
49. A prospective study of the impact of community-based azithrlycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
50. Prevalence of macrolide resistance mechanism in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
51. Novel mechanism of macrolide resistance in Streptococcus pneumoniae
52. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
53. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolone in Canada
54. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin
55. Inappropriate use of oral ciprofloxacin
56. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin
57. Fluoroquinolone resistance with Streptococcus pneumoniaein the United States
58. Prevalence of gyr A, gyr B, par C, and par E mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
59. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 results from the SENTRY Antimicrobial Surveillance Program
60. Comparative antimicroblal activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection seasson
61. Activity of the new fluoroquinolone trovafloxacin CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
62. Contribution of mutations in gyr A and par C genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
63. Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin
64. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin